Background

Extraskeletal myxoid chondrosarcoma (EMC) is a very rare sarcoma of uncertain differentiation [1] that, despite its name, does not exhibit any cartilaginous differentiation. EMC usually originates from the deep soft tissue, the thigh being the most common site [2]. Demicco and Coll. recently reported on 5 cases of molecularly confirmed EMC arising primarily in the bone [3]. On this basis, they proposed to relabel this tumor as myxochondroid sarcoma, either osseous or extraskeletal.

Microscopically, EMC can be subdivided into a conventional well-differentiated and a cellular high-grade EMC, the latter being marked by the presence of a predominantly epithelioid morphology, high mitotic rate and necrosis [1]. Cases of dedifferentiated ECM were also described [4]. EMC is marked by a specific chromosomal rearrangements, involving the NR4A3 gene locus on chromosome 9 [1,5]. More often NR4A3 (also called CHN or TEC) is fused to EWSR on chromosome 22 [6,7], although four chimeric variants were described to date [4,8,9]. NR4A3 translocation is relevant in case of differential diagnosis with other myxoid-mesenchymal neoplasms [10].

The natural history of the EMC is marked by a relatively indolent behavior with a 10-year survival rate ranging between 65% and 85%, and 40% risk of metastases at 10 years [11,12], lung being the most frequent site of secondary lesions.

Abstract

Background: Extraskeletal myxoid chondrosarcoma (EMC) is a rare subgroup within soft tissue sarcomas. Its sensitivity to chemotherapy is reported to be low.

Methods: We retrospectively reviewed a series of 11 EMC patients treated as from 2001 within the Italian Rare Cancer Network (RCN) with anthracycline-based chemotherapy. Pathologic diagnosis was centrally reviewed in all cases and confirmed by the presence of the specific chromosomal rearrangements, involving the NR4A3 gene locus on chromosome 9.

Results: Eleven patients treated with anthracycline-based chemotherapy were included (M/F: 9/2 – mean age: 52 years – site of primary: lower limb/other = 9/2 - metastatic = 11 – front line/ further line = 10/1 – anthracycline as single agent/ combined with ifosfamide = 1/10). Ten patients are evaluable for response. Overall, best response according to RECIST was: partial response (PR) = 4 (40 %), stable disease (SD) = 3, progressive disease (PD) = 3 cases. Median PFS was 8 (range 2–10) months.

Conclusions: By contrast to what reported so far, anthracycline-based chemotherapy is active in a distinct proportion of EMC patients.

Keywords: Sarcoma, Chondrosarcoma, Extraskeletal myxoid chondrosarcoma, Chemotherapy, Anthracycline, Doxorubicin, Ifosfamide
Available literature reports EMC as a disease poorly sensitive to cytotoxic chemotherapy [11-15].

We herein report on a retrospective series of 11 patients with locally advanced/metastatic EMC, molecularly confirmed by the presence of NR4A3 rearrangement, treated with anthracycline-based chemotherapy at our institution and within the Italian Rare Cancer Network.

Methods
Patients selection
We retrospectively identified 11 patients with progressive, metastatic, molecularly confirmed EMC treated with anthracycline-based chemotherapy at Fondazione IRCCS Istituto Nazionale Tumori, Milano and those included in the data-base of the Italian Rare Cancer Network, registered by other Italian institutions, from January 2001 to June 2013. The analysis was approved by the Institutional Ethics Committee.

Pathological diagnosis was centrally reviewed in all cases by 2 expert pathologists (SP and APDT) and confirmed by the evidence of NR4A3 rearrangement. All patients had evidence of Eastern Cooperative Oncology Group performance status (ECOG PS) ≤3 and an adequate bone marrow and organ function. All patients provided a written informed consent to data collection within the network and to the treatment. Data were extracted from individual patient file and analyzed.

Pathology and molecular analysis
The diagnosis was rendered according to the last WHO classification [1]. Immunoprofile assessment was performed using the antibodies and conditions detailed in Table 1.

FISH was carried out on FFPE tissue samples with commercially available EWS break apart probe (VYSIS LSI-EWSR1 dual color break apart) and with two NR4A3 specific BAC probes (obtained from C.H.O.R.I. BAC PAC resources): Spectrum Orange labeled RP11-30 L7 for the 5’ end and Spectrum Green labeled RP11-30 N20 for the 3’ end of the gene. Probe labeling and FISH procedure were carried out as previously described [16]. Cases with a morphology consistent with EMC but without the evidence of NR4A2 rearrangement were excluded from this series.

Table 1 Immunohistochemistry conditions

| Antibody     | Clone   | Company      | Dilution | Antigen retrieval |
|--------------|---------|--------------|----------|------------------|
| S100         | Polyclonal Dako | 1:4000 | citrate buffer, 15' |
| Synaptophysin| Dako- SYNAP | 1:200 | EDTA, 30' |
| EMA          | E29     | Dako         | 1:250    | EDTA, 30' |
| PPARy        | E-8     | Santa Cruz Biotechnology | 1:20 | EDTA, 30' |

Clinical assessment
Full blood cell count and biochemistry were assessed at baseline and before every administration. AE were recorded. Disease status was assessed at baseline by a whole body computed tomography scan (CT), a CT or magnetic resonance (MRI) of the site(s) of disease, and a whole body bone scan. CT/MRI were repeated after the first 2 or 3 cycles of treatment every 2–3 months.

Response to treatment was evaluated by Response Evaluation Criteria in Solid Tumor (RECIST) [17].

Statistical analysis
Progression-free survival (PFS) and overall survival (OS) were estimated with Kaplan-Meyer method [18]. Failure for PFS was progressive disease according to RECIST, or death. OS, failure was death due to any cause. For PFS and OS, patients who interrupted their treatment without evidence of disease progression and underwent complete surgery were censored at the time of surgery. Alive patients were censored at the time of the last contact.

Results
Eleven patients with measurable disease were treated with an anthracycline-based chemotherapy. Five patients with a previous diagnosis of EMC were not included in this series since diagnosis was not confirmed by the presence of NR4A3 rearrangement. Ten patients were evaluable for response (in one case treatment was interrupted early due to toxicity). Main patient characteristics were: male/female 9/2, mean age 52 years, primary arising from soft tissue/bone 10/1, locally advanced/metastatic 1/10 (lung metastases in 10 cases), ECOG PS ≤2: 11, anthracycline-based chemotherapy as front-line/further line: 10/1. Three patients underwent macroscopic complete surgery after treatment. Patient characteristics are detailed in Table 2.
| Patient ID | Gender | Age at time of chemotherapy (years) | Diagnosis | NR4A3 rearrangement | Site of primary tumor | Staging at time of initial diagnosis | Site of relapse at the time of chemotherapy | RECIST evaluation | PFS |
|------------|--------|-----------------------------------|-----------|---------------------|----------------------|--------------------------------------|---------------------------------------------|------------------|-----|
| 1          | F      | 48                                | EMC       | yes                 | thigh                | localized disease                    | abdomen, LN                                  | PR               | 7   |
| 2          | M      | 56                                | EMC       | yes                 | thigh                | localized disease                    | lung, LN                                     | PD               | 4   |
| 3          | M      | 46                                | EMC       | yes                 | thigh                | local + lung                         | lung, LN                                     | PR               | 8   |
| 4          | M      | 38                                | EMC       | yes                 | leg                  | localized disease                    | lung, bone, liver, soft tissue              | NV               | 2   |
| 5          | M      | 55                                | EMC       | yes                 | leg                  | localized disease                    | lung, LN, soft tissue                       | PR               | 8   |
| 6          | F      | 64                                | EMC       | yes                 | thigh                | localized disease                    | lung                                         | SD               | 10  |
| 7          | M      | 69                                | EMC       | yes                 | buttock              | local + lung                         | buttock, lung                                | PR               | 5   |
| 8          | M      | 55                                | EMC       | yes                 | arm                  | local + lung                         | lung, LN                                     | SD               | 7   |
| 9          | M      | 51                                | EMC       | yes                 | thigh                | localized disease                    | lung                                         | PD               | 4   |
| 10         | M      | 52                                | EMC       | yes                 | leg                  | localized disease                    | lung                                         | SD               | 5   |
| 11         | M      | 48                                | EMC       | yes                 | sacrum               | local + lung                         | lung                                         | PD               | 3   |

*Patient treated with surgery after chemotherapy, censored at the time of surgical resection; M, male; F, female; EMC, extraskeletal myxoid chondrosarcoma; LN, lymphnode; PR, partial response; SD, stable disease; PD, progressive disease; NV, not evaluable; PFS, progression free survival.
Treatment
The median number of cycles of chemotherapy was 4 (range: 1–8). Patients received anthracycline as single agent in 1 case, in combination with ifosfamide in 10. One patient stopped his treatment after the first cycle due to toxicity.

Overall, toxicity was as expected, with ≥G2 neutropenia in 60% of patients, and nausea, vomiting, asthenia, fever and mucositis as the main non-haematologic toxicities.

Pathology and molecular analysis
Immunophenotypic analysis is detailed in Table 3.

All tumors included in this series were positive for NR4A3 rearrangement. EWS was rearranged in 9 of 11 cases, as shown in Table 3. Five more patients with a previous diagnosis of EMC were eventually excluded from this series since diagnosis was not confirmed by the presence of NR4A3 rearrangement.

Response
Ten patients were assessable for response, as detailed in Table 2. The best response according to RECIST was: partial response (PR) in 4/10 cases (40%), stable disease (SD) in 3/10 (30%), with a minor response in one of them. Progressive disease (PD) was observed in 3/10 (30%) cases. Disease control rate was 70%. Responses were confirmed at 3 months. Responses were observed in 4 patients treated with epirubicin plus ifosfamide and in one patient treated with doxorubicin as a single agent. Figure 1 shows a response to doxorubicin as single agent in a previously progressive patient.

Median OS was 30 months (range 10 mos-13 years). At a median follow-up of 30 months, the estimated OS at 10-year was 50%, with 2 patients dead at the time of the present analysis and one lost to follow-up. The median PFS for the entire group was 8 months (range 2–10), with 50% patients progression-free at 6 months (Figure 2). Three patients (patent 1/7/10, Table 2) underwent complete surgical resection after chemotherapy, with evidence of a new distant relapse after 24/12/24 months from surgery, respectively.

Discussion
We retrospectively analyzed 11 patients with progressing, advanced, molecularly confirmed EMC, treated with anthracycline-based chemotherapy since 2001 within the Italian Rare Cancer Network. We observed 4 RECIST PR out of 10 patients evaluable for response, with a median PFS of 8 months and 50% patients progression-free at 6 months. As EMC is an extremely rare mesenchymal malignancy, rare cancer networks represent a valuable tool in order to collect case series, in addition to sharing and developing clinical expertise.

In fact, EMC represents a small subgroup among sarcomas and no prospective study focusing on their medical treatment is available as of today. Despite rarity, in order to collect an homogeneous series, we decided to include only cases in which diagnosis had been confirmed by the presence of NR4A3 rearrangement.

In our series the response rate to anthracycline-based chemotherapy looks greater than previously reported. The only responses to chemotherapy were described in 2001 by McGrory in 2 of 6 metastatic EMC patients responsive to a multi-agent chemotherapy [13], and more recently by Han who observed a complete remission in one patient treated with anthracyclines plus ifosfamide [19]. No objective responses were observed in the two largest retrospective series published so far, which collected cases selected over a period of 30 years starting from the 70’s [11,13]. In fact, no patient had a response amongst 10 treated with doxorubicin and dacarbazine-based regimens in the MD Anderson’s retrospective study [13] published in 1995, as well as none of the 21 patients treated with different regimens, mostly anthracycline-based, reported by Memorial Sloan Kettering Cancer Center and Royal Marsden Hospital in 2008 [11]. In the latter analysis, the best response was represented by stable disease lasting ≥ 6 months in only 25% of cases, with an estimated 40% median-PFS at 6 months. More recently, Ogura and Coll. reviewed their institutional series of 22 patients, with no response in 4 cases treated with ifosfamide-based chemotherapy [12]. An explanation for this discrepancy may well be that diagnostic criteria for EMC have improved in the last years and possibly older series may have included other histological types with overlapping morphologies, such as myoepithelial carcinomas. In particular, the analysis to detect NR3A4 translocation, which is specific of EMC, was described for the first time in 1985 [5] and was not routinely used to confirm the diagnosis until recently. It is now evident that EMC are morphologically and molecularly distinct from conventional bone chondrosarcoma, whose lack of sensitivity to chemotherapy is well known [20,21].
Indeed, EMC and conventional bone chondrosarcomas are completely unrelated.

As already mentioned, the differential diagnosis is rather broad and includes malignant myoepithelioma/myoepithelial carcinoma, whose natural history and chemosensitivity is still not well understood [1,22], but also low grade fibromyxoid sarcoma, myxoid liposarcoma and synovial sarcoma with myxoid changes [22-24]. Immunohistochemical analysis plays an important role; however, there is some degree of overlapping that may represent an additional challenge [1,24]. Although not frequently observed, synaptophysin expression [25] has been recently confirmed by gene expression profiling analysis [23]. Finally, PPR-gamma, firstly described to be involved in ECM signaling pathway [23], is also expressed in many other cancers including myxoid liposarcomas [26-28], and therefore it can hardly be diagnostically helpful. From these findings it appears that cytogenetic-molecular analysis substantially helps in distinguishing EMC from other tumor entities. For these reasons, due to the lack of NR4A3 rearrangement, we excluded 5 of 16 cases initially diagnosed as EMCS according to morphology/immunohistochemistry.

EMCS is an indolent disease and in some cases it is characterized by a slow progression also in the metastatic phase, affecting about 40% of cases. However, in case of advanced and progressive disease, a medical treatment is needed. Our series suggests that anthracycline-based chemotherapy can have a role in this setting. Of note, 3 patients of our series were completely resected after having a response to chemotherapy. None of them was cured, but they all recurred after >12 months from surgery, suggesting that chemotherapy may have played a role.

In case of resistance to conventional cytotoxic chemotherapy, further medical treatment are needed.
in EMC. We recently reported on the activity of su-
nitinib in two patients carrying a metastatic EMC
pretreated with chemotherapy [29]. These prelimi-
ary results are under confirmation in a larger series,
while a prospective study on pazopanib, another
antiangiogenic agent, is planned.

Conclusions

By contrast to what reported so far, anthracycline-
based chemotherapy is active in a distinct proportion
of EMC patients. Series like ours may serve as exter-

Crystalloidal scintillation counting was used to
measure the radioactivity in the plates. The
activity on the scintillation plates was counted
in all four quadrants of the plate, and the
results were averaged. The average activity in
each quadrant was then calculated.

The results showed that the activity in the
plate containing 5 μCi of Na125I was significantly
higher than the activity in the plates containing
5 μCi of Na131I and Na132I. The activity in the
plate containing 10 μCi of Na125I was also
significantly higher than the activity in the plates
containing 5 μCi of Na131I and Na132I.

Competing interests

None of the authors declared any financial or non-financial competing interests.

Authors’ contributions

SS contributed to study design and coordination, data collection, analysis
and interpretation, and drafted the manuscript. RS, IV, SF, FG, GA, MT, CC, AG
contributed to data collection and interpretation, and drafting. TN, GD, APD
and SP carried out the molecular genetic studies and the pathologic review,
and drafted the manuscript. PGC contributed to data analysis and
interpretation, and drafted the manuscript. All authors read and approved
the final manuscript.

Acknowledgments

We thank Toni A, Istituto Ortopedico Rizzoli, Bologna, Italy; Borgogni M,
Ospedale “S. Maria alla Gruccia”, Arezzo, Italy, for sending material of the
referred cases.

Supported by grant (10300) from the AiRC (Associazione Italiana per la
Ricerca sul Cancro) to Pilotti S.

Author details

1 Adult Mesenchymal Tumor Medical Oncology Unit, Cancer Medicine
Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
2 Experimental Molecular Pathology Unit, Department of Pathology,
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
3 Cancer Medicine, Oncologia Medica Azienda Ospedaliera della Provincia di Lecco, Lecco, Italy.
4 Chemotherapy Department, Istituto Ortopedico Rizzoli, Bologna, Italy.
5 Oncology, SS Antonio e Biagio General Hospital, Alessandria, Italy.
6 Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Fondazione Pascale,
Naples, Italy.
7 Rare Cancer Network, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
8 Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
9 Department of Anatomic Pathology, General Hospital of Treviso, Treviso, Italy.

Received: 13 November 2013 Accepted: 13 December 2013
Published: 18 December 2013

References

1. Fletcher CDM, et al. eds. World Health Organization (WHO) Classification of Tumours of Soft tissue and Bone. Pathology and Genetics. Lyon: IARC Press; 2013.
2. Meis-Kindblom JM, Bergh P, Gunterberg B, Kindblom LG. Extraskeletal
myxoid chondrosarcoma: a reappraisal of its morphologic spectrum and
prognostic factors based on 117 cases. Am J Surg Pathol 1999,
23:536–550.
3. Dernisco EG, Wang VA, Madewell JE, Huang D, Bui MM, Bridge JA, Meis JM: Osseous myxochondrosarcoma: a detailed study of 5 cases of
extraskeletal myxoid chondrosarcoma of the bone. Am J Surg Pathol 2013,
37:752–762.
4. Antonescu CR, Argani P, Erlandson RA, et al: Skeletal and extraskeletal
myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer 1998, 83:1504–1521.
5. Hinrichs SH, Jaramillo MA, Gumerlock PH, et al: Myxoid chondrosarcoma
with a translocation involving chromosomes 9 and 22. Cancer Genet
Cytogenet 1985, 14:219–226.
6. Hirabayashi Y, Ishida T, Yoshida MA, et al: Translocation (9;22)(q22;q12). A recurrent chromosome abnormality in extraskeletal myxoid
chondrosarcoma. Cancer Genet Cytogenet 1995, 81:33–37.
7. Steenman G, Andersson H, Mandahl N, Meis-Kindblom JM, Kindblom LG: Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in
extraskeletal myxoid chondrosarcoma. Int J Cancer 1995, 62:398–402.
8. Stacchiotti S, Meis-Kindblom JM, Kindblom LG, et al: Fusion of the EWS-related
gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res 1999, 59:5084–5087.
9. Stacchiotti S, Meis-Kindblom JM, Kindblom LG, et al: Fusion of the TAF2N gene to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res 1999, 59:5084–5087.
10. Flucke U, Tops BB, Verdijk MA, et al: NFRA3 rearrangement reliably
distinguishes between the clinicopathologically overlapping entries
myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid
chondrosarcoma. Virchows Arch 2012, 460:621–628.
11. Driton AD, Popat S, Bhuchar G, et al: Extraskeletal myxoid
chondrosarcoma: a comparative clinicopathologic,
immunohistochemical, and ultrastructural, and molecular study indicating neuro-
derived differentiation. Histopathology 2011, 59:514–524.
12. Kaplan WE, Meier P: Nonparametric estimation from incomplete
observations. J Am Stat Assoc 1958, 53:457–481.
13. Han K, Sun YJ, Shen Z, et al: extraskeletal myxoid
chondrosarcoma: a report of 23 patients treated at a single
referral center with long-term follow-up. Arch Orthop Trauma Surg 2012,
132:1379–1386.
14. Perrone F, Tabano S, Colombo F, et al: p15INK4b, p14ARF, and
p16INK4a inactivation in sporadic and neurofibromatosis type 1-
related malignant peripheral nerve sheath tumors. Cancer Genet Cytogenet
1995, 83:337–345.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate
the response to treatment in solid tumors. European Organization for
Research and Treatment of Cancer. J Natl Cancer Inst 2000, 92:307–318.

proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997, 94:237–241.

28. Demetri GD, Fletcher CD, Mueller E, et al: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999, 96:3951–3956.

29. Stacchiotti S, Dagrada G, Morosi C, et al: Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res 2012, 2:22.

doi:10.1186/2045-3329-3-16
Cite this article as: Stacchiotti et al: Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. Clinical Sarcoma Research 2013 3:16.